For these studies, we evaluated seven mouse models of high-risk NB: The MYCN-amplified (and therefore high-risk) SIMA and MHH-NB-11 models; the high-risk SK-N-FI model established from a metastatic site that is MYCN-WT but poorly differentiated; the MYCN-WT; the ALK mutant FELIX patient-derived xenograft (PDX) model (Sano et al., 2019a); CHLA20, a MYCN-WT PDX established at the progression of disease (Schoen et al., 2018); and two MYCN-amplified PDX models, COG-N452 and COG-N-561 (Lochmann et al., 2018b; Schoen et al., 2018). This evidence concerns the gene MYCN and neuroblastoma.